03759 PHARMARON
- 10.420
- +0.470+4.72%
PHARMARON News
Kanglong Chemical (300759): Short-term 24Q1 performance under pressure, order trends are good, and recovery is expected
Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
Kanglong Chemical (300759) Company Information Update Report: 2024Q1 performance is under phased pressure, new business promotion opens up room for growth
Kanglong Chemical (300759): Signed a new rapid growth integrated platform showing resilience
Kanglong Chemical (300759): New orders increased 20% year over year + expected to gradually pick up throughout the year
Kanglong Chemical (300759): Overseas front-end R&D demand is picking up, and profit margins are expected to improve quarterly
Kanglong Chemical (300759): New orders are improving, and month-on-month improvements can be expected
Kanglong Chemical (300759): Waiting for the inflection point, the order side shows signs of improvement
Kanglong Chemical (300759): New Q1 orders increased by more than 20% year-on-year, demand for downstream innovation gradually picked up
Minsheng Securities released a research report on April 26 stating that Kanglong Chemical (300759.SZ) was given a recommended rating. The main reasons for the rating include: 1) laboratory services are recovering month-on-month, and new orders for small m
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy
Kanglong Chemical (300759): Marginal improvement in order signing is optimistic about the upward trend throughout the year
Kanglong Chemical (300759): Performance is under pressure and new orders have ushered in a trend improvement
Kanglong Chemical (300759): Beautiful clinical service, impressive number of CMO projects
Capital Securities released a research report on April 12 stating that Kanglong Chemical (300759.SZ) was given a purchase rating. The main reasons for the rating include: 1) the decline in investment and financing sentiment affects business performance su
Kanglong Chemical (300759): Main business performance is stable and waiting for marginal improvement
Southwest Securities released a research report on April 8 stating that Kanglong Chemical (300759.SZ) was given a purchase rating, and the target price was 25.22 yuan. The main reasons for the rating include: 1) steady growth on the revenue side, which is
Kanglong Chemical (300759): Steady business growth and back-end capabilities are expected to be gradually realized
Kanglong Chemical (300759) 2023 Report Review: Annual revenue and profit growth trend, optimistic about the long-term steady development of integrated CXO leaders
Kanglong Chemical (300759) Comment: Steady growth in 23 years is optimistic about the integrated business model
Analysis
Price Target
No Data
